Investment Rating - The report maintains a "Strong Buy" rating for JD Group [3] Core Insights - JD Group's Q4 2025 performance showed better-than-expected retail profits despite challenges in the electronics category due to subsidy reductions and high base effects. Retail revenue was 3,019 billion yuan, down 1.7% year-on-year, while total revenue reached 3,523 billion yuan, up 1.5% year-on-year [1][5] - The report anticipates steady growth in both group and retail revenues for 2026, with a continued reduction in losses from the food delivery business. The long-term outlook remains positive due to JD's solid operational barriers [1][5] Financial Performance Summary - For Q4 2025, JD Group's Non-GAAP net profit was 1.1 billion yuan, a significant decline of 90% year-on-year, but better than the consensus expectation of a 95.2% decline [1][5] - The report projects revenue growth rates of 7% for 2024, 13% for 2025, and 8% for 2026, with Non-GAAP net profits expected to be 27 billion yuan in 2025 and 28.9 billion yuan in 2026 [2][6] - The target price is set at 128.9 HKD per share, with the current share price at 106.6 HKD, indicating a potential upside [3] Shareholder Returns - JD Group plans to return approximately 10% to shareholders through share buybacks and dividends, with a total buyback of about 3 billion USD in 2025 and a cash dividend of 0.5 USD per share [5][6]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][5] Core Insights - The company achieved a revenue of USD 15.26 billion in 2025, representing a year-on-year growth of 4.4%, with a net profit of USD 1.2 billion, up 6.8% year-on-year. The second half of 2025 saw revenue of USD 7.43 billion, a slight increase of 1.6%, while net profit decreased by 0.24% to USD 570 million [5][6] - The company anticipates a strong performance in 2026, with core brand Milwaukee expected to grow by 10-12%, driven by recovering demand in North America and infrastructure projects. Overall revenue growth is projected to be in the mid-single digits [7][8] - The company has adjusted its profit forecasts for 2026-2027, now expecting net profits of USD 1.42 billion and USD 1.66 billion, respectively, with corresponding EPS of USD 0.8 and USD 0.9 [5][8] Financial Summary and Valuation Metrics - The company’s financial metrics for 2024A to 2028E are as follows: - Revenue (million USD): 14,622 (2024A), 15,260 (2025A), 16,536 (2026E), 17,796 (2027E), 18,994 (2028E) - Net Profit (million USD): 1,122 (2024A), 1,198 (2025A), 1,421 (2026E), 1,656 (2027E), 1,868 (2028E) - Gross Margin (%): 40.3 (2024A), 41.2 (2025A), 41.5 (2026E), 42.0 (2027E), 42.5 (2028E) - EPS (diluted, USD): 0.6 (2024A), 0.7 (2025A), 0.8 (2026E), 0.9 (2027E), 1.0 (2028E) [8]

Investment Rating - The report assigns an "Accumulate" rating for HashKey HLDGS (03887) with a target price of HK$7.83 [2][5]. Core Insights - HashKey is positioned as a leading compliant digital asset exchange in Asia, capitalizing on the Web3 regulatory advantages and aiming to capture significant market share in the compliant digital asset space [4][14]. - The company has a strong market presence, holding over 75% of the market share among licensed platforms in Hong Kong, and is expanding into global markets such as Bermuda and Dubai [4][6]. - HashKey's business model is evolving from a retail-driven approach to focusing on institutional clients and Omnibus partners, enhancing revenue quality and sustainability [4][5]. - Financial forecasts indicate a significant revenue increase, with projected revenues of HK$7.21 billion in 2024, HK$7.0 billion in 2025, HK$11.5 billion in 2026, and HK$20.2 billion in 2027, despite ongoing net losses [2][5][47]. - The company is expected to benefit from upcoming regulatory developments in Hong Kong, including the issuance of stablecoin licenses, which could enhance its competitive position [6][4]. Financial Summary - Revenue projections for HashKey are as follows: - 2024: HK$721 million - 2025: HK$700 million - 2026: HK$1.149 billion - 2027: HK$2.020 billion - Corresponding net profits are projected to be negative, with estimates of -HK$1.19 billion in 2024, -HK$953 million in 2025, -HK$754 million in 2026, and -HK$150 million in 2027 [2][5]. - The company is expected to optimize its cost structure, leading to a gradual reduction in losses as operational leverage improves [4][5]. Business Model - HashKey operates through three main business segments: 1. **Transaction Facilitation Services**: This includes exchange services, OTC trading, and custody services, which are expected to contribute approximately 70% of total revenue [23][27]. 2. **On-chain Services**: This segment includes staking, tokenization, and blockchain infrastructure services [23][24]. 3. **Asset Management Services**: This involves managing digital asset investment funds, including venture capital and secondary market funds [24][27]. Market Position and Strategy - HashKey is strategically positioned as a compliant digital asset exchange, leveraging its licenses and regulatory framework to attract institutional and retail clients [4][14]. - The company has a concentrated ownership structure, with key stakeholders holding 75.19% of shares, ensuring strategic alignment and stability [15][16]. - The management team comprises experienced professionals from traditional finance and technology sectors, enhancing the company's operational capabilities [19][21].

Investment Rating - The report assigns a "Buy" rating to the company, Tianhong International Group, with a target price of HKD 10.20 based on a 2026 PE of 8X [8][19]. Core Insights - Tianhong International Group is recognized as a global leader in yarn production, with a significant portion of its production capacity located in Vietnam. The company has successfully cleared high inventory levels and is entering a period of profit growth [3][19]. - The report forecasts that the company's net profit attributable to shareholders will reach RMB 8.9 billion, RMB 10.4 billion, and RMB 11.3 billion for the years 2025, 2026, and 2027, respectively, reflecting year-on-year growth rates of 60.5%, 17.2%, and 8.7% [18][19]. Summary by Sections 1. Company Overview - Tianhong International Group, founded in 1997, is one of the largest suppliers of core-spun cotton textiles globally. The company has strategically expanded its yarn production capacity in Vietnam since 2006, which has positioned it well in the market [19][20]. 2. Financial Analysis - The company's revenue for 2024 is projected at RMB 23.03 billion, with a slight increase of 1.3% year-on-year. The gross profit is expected to be RMB 2.863 billion, and the net profit attributable to shareholders is forecasted at RMB 554 million, marking a significant recovery from previous losses [6][18]. - The report highlights that 76.1% of the company's costs are related to raw materials, primarily cotton, indicating that profit margins are sensitive to fluctuations in cotton prices [19][34]. 3. Future Outlook - The global yarn market is expected to grow at a CAGR of 5.9% from 2025 to 2032, with the market size projected to reach RMB 12,602.9 billion by 2032. Tianhong's yarn revenue is anticipated to account for approximately 2.1% of this market in 2024 [42][43]. - The company is actively working on debt repayment and reducing leverage, which is expected to lower financial expenses and enhance profitability. It plans to repay RMB 8-10 billion in debt annually over the next three years [44][48].

Investment Rating - The report maintains a "Buy" rating for JD Group-SW (9618.HK) [1] Core Insights - JD Group's Q4 2025 revenue reached 352.3 billion RMB, showing a year-over-year increase of 2% and a quarter-over-quarter increase of 18%, exceeding Bloomberg consensus expectations [4][10] - The adjusted net profit attributable to shareholders for Q4 2025 was 1.1 billion RMB, significantly above Bloomberg consensus expectations [10] - The company reported a total shareholder return of approximately 10% for 2025, with a share buyback amounting to about 3 billion USD and cash dividends of around 1.4 billion USD [4] Summary by Relevant Sections Overall Performance - JD Group's Q4 2025 revenue slightly exceeded expectations, driven by strong advertising revenue from daily necessities and cross-selling in the food delivery segment [6] - The retail segment's revenue decreased by 2% year-over-year to 301.9 billion RMB, impacted by high base effects in the electronics category, while daily necessities grew by 12% [6][10] Profitability - Q4 2025 gross profit was 55.1 billion RMB, with a gross margin of 15.6% [14] - Operating profit was -5.8 billion RMB, reflecting a significant decline year-over-year [14] - The net profit for Q4 was -1.2 billion RMB, with a net margin of -0.3% [14] Future Projections - Revenue forecasts for 2026-2028 are 1.4 trillion, 1.5 trillion, and 1.58 trillion RMB respectively, with expected net profits of 23.7 billion, 36.1 billion, and 47.5 billion RMB [19] - The report anticipates continued improvement in operational efficiency and profitability from the food delivery business [9][19] Valuation - The target market capitalization for JD Group in 2026 is estimated at 432.9 billion RMB, corresponding to a target price of 136 RMB per share [19][20] - The report uses a sum-of-the-parts (SOTP) valuation method to arrive at this target price [19]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 3.18, compared to the current price of HKD 2.45 [3]. Core Insights - The company has shown significant results from its asset-light transformation, with an increase in market share in the used car sector [1]. - The overall performance for 2025 met expectations, with total revenue reaching RMB 11.549 billion, a year-on-year increase of 16.27%. The net profit attributable to shareholders was RMB 1.199 billion, up 48.03% year-on-year [8]. - The company’s SaaS service revenue surged by 149.53% year-on-year, contributing to a substantial increase in platform business revenue [8]. Financial Forecasts - Total revenue projections for 2026, 2027, and 2028 are RMB 14.203 billion, RMB 16.078 billion, and RMB 18.323 billion, respectively, with growth rates of 22.98%, 13.20%, and 13.96% [2]. - Net profit attributable to shareholders is expected to be RMB 1.486 billion, RMB 1.765 billion, and RMB 2.035 billion for the same years, reflecting growth rates of 23.95%, 18.77%, and 15.27% [2]. - The company’s earnings per share (EPS) is projected to increase from RMB 0.18 in 2025 to RMB 0.30 by 2028 [2]. Business Highlights - The company’s auto financing transaction volume reached 844,000 transactions in 2025, with a financing transaction amount of RMB 75.148 billion, marking an 8.69% increase year-on-year [8]. - The proportion of used car financing transactions increased significantly, accounting for 63.63% of transaction volume and 55.99% of transaction value by the end of 2025 [8]. - The average balance of receivables for financing leases was RMB 29.785 billion, a year-on-year increase of 14.55%, with a net interest margin of 6.00% [8].

Investment Rating - The investment rating for JD Health (06618) is maintained as "Buy" [2] Core Insights - JD Health reported a significant revenue growth of 26.3% year-on-year, reaching 73.44 billion RMB in 2025, which exceeded market expectations by 3.1% [7] - The company's Non-IFRS operating profit margin and net profit margin reached historical highs, benefiting from optimized revenue structure and improved operational efficiency [7] - The company continues to see strong growth in its core e-commerce business, with pharmaceutical and health product sales increasing by 24.8% to 60.9 billion RMB [7] - The active user base reached 217.7 million, a 19% increase year-on-year, with over 100 new drugs launched on the platform in 2025 [7] - JD Health is actively exploring AI applications across various scenarios, enhancing platform conversion efficiency [7] Financial Forecast - Revenue projections for 2026-2028 are estimated at 86.26 billion RMB, 98.96 billion RMB, and 111.65 billion RMB respectively, with corresponding net profits of 6.57 billion RMB, 7.63 billion RMB, and 8.72 billion RMB [6][8] - The company is expected to maintain a robust growth trajectory, with a net profit growth rate of 5.6% in 2026 and 16.84% in 2027 [6] - The earnings per share (EPS) is projected to increase from 1.70 RMB in 2025 to 2.40 RMB in 2028 [6] Key Financial Metrics - The company reported a cash reserve of 69.5 billion RMB at the end of 2025 [7] - The return on equity (ROE) is expected to improve from 8.95% in 2025 to 9.76% in 2028 [6] - The price-to-earnings (P/E) ratio is projected to decrease from 28.73 in 2025 to 17.72 in 2028, indicating potential valuation improvement [6]

Investment Rating - The investment rating for the company is upgraded to "Buy" [2][7]. Core Insights - The company reported a revenue of 217.15 billion yuan for 2025, representing a year-on-year growth of 18.8%, with a net profit of 6.65 billion yuan, up 7.2% year-on-year [7]. - In Q4 2025, the company achieved a revenue of 63.53 billion yuan, a 21.9% increase year-on-year, and a net profit of 2.04 billion yuan, growing 17.8% year-on-year [7]. - Internal revenue from JD Group reached 26.65 billion yuan in Q4 2025, up 68.1% year-on-year, accounting for 42.0% of total revenue, while external revenue was 36.89 billion yuan, a 1.8% increase year-on-year, making up 58.0% of total revenue [7]. - The company is focusing on expanding its integrated supply chain services, offering differentiated high-standard services, which is expected to drive rapid revenue growth [7]. - The company is projected to achieve revenues of 265.17 billion yuan, 291.21 billion yuan, and 316.91 billion yuan for the years 2026, 2027, and 2028 respectively, with net profits of 8.32 billion yuan, 9.39 billion yuan, and 10.36 billion yuan for the same years [7]. Financial Performance Summary - The company’s revenue growth rates are forecasted at 22.12% for 2026, 9.82% for 2027, and 8.82% for 2028 [6]. - The projected earnings per share (EPS) are 1.25 yuan for 2026, 1.41 yuan for 2027, and 1.55 yuan for 2028 [6]. - The price-to-earnings (PE) ratio is expected to decrease from 8.94 in 2026 to 7.18 in 2028, indicating strong earnings growth potential [6]. - The return on equity (ROE) is projected to be 13.25% in 2026, 13.04% in 2027, and 12.61% in 2028, reflecting a solid profitability outlook [6].

Investment Rating - The report maintains an "Outperform" rating for the company [5] Core Insights - The company is the third-largest foundry globally, benefiting from the rise of domestic enterprises and the trend of localized manufacturing [1][11] - The semiconductor industry has long-term growth potential, characterized by cyclical and growth aspects, with global semiconductor sales expected to reach a record high of $791.6 billion in 2025 [2][34] - The company's revenue is projected to grow from $31 billion in 2017 to $93 billion in 2025, with a CAGR of 15% [20] - The company maintains a high capacity utilization rate, expected to reach 95.7% by Q4 2025, driven by the increasing demand from Chinese chip design companies [2][55] Financial Projections - Revenue and net profit forecasts for 2025 are $9.3 billion and $685 million, respectively, with a net profit CAGR of 18% from 2017 to 2025 [4][20] - The company’s gross margin is expected to be 21% in 2025, with over 90% of revenue coming from integrated circuit foundry services [23][29] - The company plans to increase its capital expenditure significantly, reaching $8.1 billion by 2025 to support capacity expansion [56][59] Market Dynamics - The company is positioned to benefit from the increasing number of Chinese chip design firms, which are expected to grow from 1,380 in 2017 to 3,901 by 2025, with a CAGR of 14% [43] - The demand for 12-inch wafers is rising, with their revenue share expected to increase to 77% by 2025, while the share of 8-inch wafers declines to 23% [29][31] - The global semiconductor sales are projected to continue double-digit growth into 2026, indicating a robust market environment [34]

Investment Rating - The report maintains an "Outperform" rating for Hutchmed (China) Limited with a target price of HK$38.11, reflecting a potential upside from the current price of HK$22.18 [2][25]. Core Insights - Hutchmed reported a total revenue of USD 549 million for FY25, a decrease of 13% year-on-year, with oncology/immunology combined revenue at USD 290 million, down 21% year-on-year. This decline was attributed to a high base effect from a previous milestone payment and a drop in domestic sales of key products [3][18]. - The management expects a recovery in sales for FY26, projecting oncology/immunology revenue between USD 330 million and USD 450 million, which includes potential income from licensing the ATTC platform [3][19]. - The company is focusing on the development of its Antibody-Targeted Toxin Conjugate (ATTC) platform, with two products currently in global clinical development [6][19]. Financial Performance - For FY25, Hutchmed's net profit attributable to shareholders was USD 460 million, significantly boosted by a one-time gain of USD 480 million from the sale of a subsidiary [3][18]. - R&D expenses were USD 150 million, down 30% year-on-year, while SG&A expenses were USD 100 million, a decrease of 9% year-on-year [3][18]. - The company had cash and cash equivalents of USD 1.37 billion at the end of FY25, indicating a strong liquidity position [3][18]. Product Performance - Fruquintinib (ex-China) sales reached USD 370 million, up 26% year-on-year, driven by growth in the Japanese market and improved reimbursement coverage in Europe. However, domestic sales of Fruquintinib (China) fell to USD 76.9 million, down 11% year-on-year [19][23]. - The report highlights that the sales of core products in China showed signs of improvement in the second half of FY25, with Fruquintinib (China) revenue increasing by 29% quarter-on-quarter [19][23]. Clinical Development - HMPL-A251, a first-in-class ATTC targeting HER2, has shown promising anti-tumor activity comparable to existing therapies and is currently in a global Phase I/IIa clinical trial [20][24]. - HMPL-A580, another ATTC candidate targeting EGFR, has also entered clinical development, with a global Phase I trial initiated in March 2026 [21][22]. - Management plans to submit a global clinical trial application for a third ATTC candidate, HMPL-A830, within 2026 [22].